{"filings":[{"id":96846,"accession_number":"0001213900-26-051028","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.01","3.02","5.02","9.01"],"status":"ready","headline":"Advanced Biomed completes AI pivot with acquisition of Acellent Technologies","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.","Strategic pivot from life sciences to AI development; CEO Yi Lu mutually separated, receives 39,999 shares as severance.","Xiaomin Chen appointed CEO, director, and chairman effective April 28; he has 20+ years AI experience including Google.","Chen's base salary set at $12,000/month; eligible for bonuses and equity incentives.","Chen is the sole shareholder of the acquired entity, creating a direct material interest in the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96845,"accession_number":"0001213900-26-043557","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Advanced Biomed enters $600K unsecured loan at 10% interest, 6-month term","event_type":"debt","confidence":"high","bullets":["Loan of $600,000 from Jie Wang, unsecured, at 10% annual interest, maturing 6 months from disbursement.","Proceeds to be used for general operations; prepayment allowed without penalty or premium.","Term may be extended for an additional 6 months upon mutual written agreement of the parties.","Event of default triggers acceleration and borrower responsible for enforcement costs including attorneys' fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96844,"accession_number":"0001213900-26-040030","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Advanced Biomed agrees to acquire Acellent Technologies for 270K shares valued at $1.08M","event_type":"m_and_a","confidence":"high","bullets":["Acquiring 100% of Acellent Technologies (Hong Kong), an AI-powered financial verification company.","Purchase price: 270,000 shares of ADVB common stock valued at $4.00/share, total $1,080,000.","Closing subject to completion of due diligence and receipt of regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111110,"accession_number":"0001213900-26-036424","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Advanced Biomed CTO and director Steven I-Fang Cheng resigns; CFO Mingze Yin appointed to board","event_type":"leadership","confidence":"high","bullets":["Steven I-Fang Cheng resigned as director and CTO effective March 25, 2026; no disagreement with company.","Mingze Yin, CFO, appointed as director effective March 25, 2026.","No family relationships or transactions requiring disclosure for Mr. Yin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111109,"accession_number":"0001213900-26-028330","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Advanced Biomed regains Nasdaq compliance after reverse stock split; stock remains listed","event_type":"regulatory","confidence":"high","bullets":["Received Panel decision on March 12, 2026 confirming compliance with Minimum Bid Price Rule.","Reverse stock split completed Feb 20, 2026 brought closing bid price to $1.00+.","Company will remain listed on Nasdaq subject to one-year Panel monitor under Rule 5815(d)(4)(A).","Previously appealed delisting determination on Jan 21, 2026; hearing held Feb 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111108,"accession_number":"0001213900-26-020807","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Advanced Biomed announces 1-for-20 reverse stock split to regain Nasdaq compliance","event_type":"other","confidence":"high","bullets":["Reverse split effective Feb 20, 2026; every 20 shares become 1 share, par value unchanged $0.001.","Outstanding shares reduced from 27,290,710 to approx 1,364,536; authorized shares unchanged.","New CUSIP 00752P203; stock continues trading under symbol ADVB; no fractional shares issued.","Split aims to meet Nasdaq minimum bid price of $1.00 per share.","Stockholder approval obtained via written consent on Jan 12, 2026; board set ratio Jan 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111104,"accession_number":"0001213900-26-014247","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K/A","filed_at":"2026-02-10T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Advanced Biomed issues 1.65M shares as commitment fee for $25M equity line","event_type":"other","confidence":"high","bullets":["On Jan 30, 2026, issued 1,650,710 shares to HELENA GLOBAL for commitment fee under $25M equity line.","Shares valued at $500,000 at issuance; issued under Section 4(a)(2) exemption.","Issuance fulfills obligation under the agreement originally disclosed on June 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111107,"accession_number":"0001213900-26-010809","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Advanced Biomed raises $248k via private placement of 4M shares at $0.062","event_type":"other_material","confidence":"high","bullets":["Issued 4,000,000 shares of common stock at $0.062/share for total proceeds of $248,000.","Securities Purchase Agreement entered Jan 28, 2026, closed Jan 29, 2026.","Private placement exempt from registration under Section 4(a)(2) of Securities Act and Regulation S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111106,"accession_number":"0001213900-26-008254","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Advanced Biomed enters supplemental agreement for $6.9M debt repayment from spun-off subsidiary","event_type":"other_material","confidence":"high","bullets":["Advanced Biomed acknowledged $6,925,549 debt owed by Advanced Biomed (HK) Limited, its spun-off subsidiary.","Subsidiary agreed to repay the full amount within one year from January 26, 2026.","Supplemental agreement amends the prior Spin-Off Agreement dated December 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111105,"accession_number":"0001213900-26-006281","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Advanced Biomed faces Nasdaq delisting after failing minimum bid price; appeals with reverse split plan","event_type":"other_material","confidence":"high","bullets":["Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.","Company appealed on Jan 21, 2026, staying suspension pending Nasdaq hearings panel decision.","Regain compliance plan includes reverse stock split approved Jan 12, 2026, effective on/after Feb 13, 2026.","No assurance that panel will grant continued listing or that compliance will be achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127749,"accession_number":"0001213900-25-126584","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan","event_type":"m_and_a","confidence":"high","bullets":["Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.","Transaction closed on December 23, 2025; board unanimously approved.","CEO cites evolving China regulatory requirements on clinical trials and data as reason for divestiture.","All clinical trials will now be centralized and conducted through the Taiwan subsidiary.","Buyer Wei Ha Hui is an unrelated third party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144511,"accession_number":"0001213900-25-089566","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Advanced Biomed launches A+PerfusC 3D cell culture platform for precision medicine","event_type":"other_material","confidence":"high","bullets":["A+PerfusC is a compact perfusion 3D cell culture incubator with automated perfusion and environmental control, mountable on a microscope for real-time observation.","System supports up to 12 days continuous culture, 8 independent channels per plate, 600 tumor spheroids per row, and 4,800 spheroids per plate.","Global 3D cell culture market valued at $2.32B in 2025, projected to exceed $4.71B by 2030 (CAGR >15.6%) per Mordor Intelligence.","Mass-production development is ongoing; commercialization will follow finalization of mass production and quality control standards.","Potential applications include personalized oncology, drug screening, regenerative medicine, organoid studies, and stem cell research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144510,"accession_number":"0001213900-25-067328","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Advanced Biomed receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ADVB on July 18, 2025, of bid price below $1.00 for 32 consecutive business days.","Company has until Jan 14, 2026 to regain compliance; must close at $1.00+ for 10 consecutive days.","If not cured, ADVB may get an extra 180 days if it meets other Nasdaq initial listing standards.","Company may consider a reverse stock split or other options to remedy the deficiency.","Common stock continues trading under symbol ADVB on Nasdaq Capital Market with no immediate impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162878,"accession_number":"0001213900-25-052234","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Advanced Biomed secures up to $25M equity purchase agreement with Helena Global","event_type":"other_material","confidence":"high","bullets":["Company enters purchase agreement with HELENA GLOBAL for up to $25M of common stock.","Company may sell shares at its discretion; purchase price equals lowest intraday price during a 3-day pricing period.","Maximum advance capped at the lesser of 25% of 5-day average daily value traded or $2M per draw.","Investor ownership limitation set at 4.99% of outstanding common stock.","Agreement dated June 6, 2025; shares to be sold in reliance on Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162877,"accession_number":"0001213900-25-048271","cik":1941029,"company_name":"Advanced Biomed Inc.","ticker":"ADVB","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Advanced Biomed board member Dr. Hung To Pau resigns, Steven I-Fang Cheng appointed","event_type":"leadership","confidence":"high","bullets":["Dr. Hung To Pau resigned from the Board of Directors on May 23, 2025 for personal reasons.","Board appointed Steven I-Fang Cheng as a director, effective May 23, 2025.","No details on compensation or specific reason for resignation provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}